Gapping up
In reaction to strong earnings/guidance: KMX +14.5%, JRJC +10%.
M&A news: SHPG +14.6% (confirms rejection of AbbVie (ABBV) proposal), APP +5.9% (Bloomberg discusses that APP may be a possible takeover target), ABBV +2.4% (confirms merger proposal for Shire (SHPG), later rejected b SHPG), S +1.4% (nearing $40 bln financing for TMUS deal, according to reports), TMUS +0.8% (Sprint (S) nearing $40 bln financing for TMUS deal, according to reports).
Other news: DEJ +20% (to own 99% of Woodrush Production; co announced that, subject to final approval from the TSX, it will acquire a further 24% Working Interest in its legacy Woodrush oil and gas production project), COCO +17.9% (rebounding modestly from yesterday's 66% decline), LOGI +2.4% (still checking), FDO +2.1% (Carl Icahn sends letter to FDO urging co be put up for sale immediately), CBST +2.1% (announced acceptance of Ceftolozane/Tazobactam New Drug Application with priority review), DEO +0.8% (plans to increase stake in United Spirits to 55%, according to reports).
Analyst comments: AN +4.4% (upgraded to Buy from Neutral at Goldman), ENTG +2.2% (target raised to $15 at Stifel), BBRY +1% (target raised to $12 at RBC Capital Mkts)
In reaction to strong earnings/guidance: KMX +14.5%, JRJC +10%.
M&A news: SHPG +14.6% (confirms rejection of AbbVie (ABBV) proposal), APP +5.9% (Bloomberg discusses that APP may be a possible takeover target), ABBV +2.4% (confirms merger proposal for Shire (SHPG), later rejected b SHPG), S +1.4% (nearing $40 bln financing for TMUS deal, according to reports), TMUS +0.8% (Sprint (S) nearing $40 bln financing for TMUS deal, according to reports).
Other news: DEJ +20% (to own 99% of Woodrush Production; co announced that, subject to final approval from the TSX, it will acquire a further 24% Working Interest in its legacy Woodrush oil and gas production project), COCO +17.9% (rebounding modestly from yesterday's 66% decline), LOGI +2.4% (still checking), FDO +2.1% (Carl Icahn sends letter to FDO urging co be put up for sale immediately), CBST +2.1% (announced acceptance of Ceftolozane/Tazobactam New Drug Application with priority review), DEO +0.8% (plans to increase stake in United Spirits to 55%, according to reports).
Analyst comments: AN +4.4% (upgraded to Buy from Neutral at Goldman), ENTG +2.2% (target raised to $15 at Stifel), BBRY +1% (target raised to $12 at RBC Capital Mkts)